Published online before print February 28, 2007, 10.1148/radiol.2431050658
MR Monitoring of Cyclooxygenase-2 Inhibition of Angiogenesis in a Human Breast Cancer Model in Rats1
Laure S. Fournier, MD,
Viktor Novikov, MD,
Vincenzo Lucidi, MD,
Yanjun Fu, PhD,
Theodore Miller, MD,
Eugenia Floyd, DVM,
David M. Shames, MD and
Robert C. Brasch, MD
1 From the Center for Pharmaceutical and Molecular Imaging, University of California, San Francisco, San Francisco, Calif. Received April 20, 2005; revision requested June 15; final revision received February 28, 2006; accepted April 6; final version accepted August 1. Supported in part by National Institutes of Health grant no. RO1 CA82923. L.S.F. supported by a postdoctoral stipend from the Association pour la Recherche sur le Cancer (2001) and the Philippe Foundation (2002).
Address correspondence to L.S.F., Department of Radiology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France (e-mail: laure.fournier{at}gmail.com).
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1: Time line and representative MR images show the treatment and imaging protocol. When the tumors grew to be 1.0–1.5 cm in diameter, they were examined with MR imaging (day 0). Celecoxib or saline administration began the next day (day 1). Tumors were examined again 24 hours after the first dose was administered (day 2). Celecoxib treatment and saline administration continued for 7 days. The final MR examination was performed approximately 1 hour after the seventh dose of celecoxib or saline was administered (day 7).
|
|
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2: Histogram shows mean KPS values and standard deviations (error bars) at baseline and at 1 day and 7 days after administration of celecoxib (Treated) or saline (Controls). There was a significant difference (*) between baseline KPS values (x-axis, in milliliters per minute per 100 mL of tissue) and KPS values at day 7 in the rats treated with celecoxib.
|
|
View larger version (161K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3a: Representative light microscopic sections from two tumors immunohistochemically stained for CD31 and specific for endothelial cells (arrows), which stain dark brown. (Hematoxylin-eosin stain; original magnification, x20.) (a) Section shows tumors in a control rat have high microvessel density. (b) Section shows a tumor has much lower vessel density after 7 days of antiangiogenic treatment with celecoxib.
|
|
View larger version (157K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3b: Representative light microscopic sections from two tumors immunohistochemically stained for CD31 and specific for endothelial cells (arrows), which stain dark brown. (Hematoxylin-eosin stain; original magnification, x20.) (a) Section shows tumors in a control rat have high microvessel density. (b) Section shows a tumor has much lower vessel density after 7 days of antiangiogenic treatment with celecoxib.
|
|
Copyright © 2007 by the Radiological Society of North America.
